Cardiometabolic Disorders News

Women who identify as American Indian or Alaska Native are more likely to have type 2 diabetes, to have obesity, to smoke and to report exposure to trauma and violence than white women, significantly increasing their risk for CVD.

SGLT2 inhibition was associated with reduced 5-year risk for stroke among patients with concomitant atrial fibrillation and diabetes, according to a study in the Journal of the American Heart Association.

The FDA has approved sotagliflozin, a dual SGLT1/SGLT2 inhibitor, for reduction of risk for death, HF hospitalization and urgent HF visits in patients with HF and in those with certain CV risk factors, Lexicon Pharmaceuticals announced.

Adults with higher cortisone levels as measured in their scalp hair may be more likely to develop future cardiovascular disease, according to a presenter at the European Congress on Obesity.

Use of a swallowable gastric balloon in conjunction with a GLP-1 receptor agonist induced a mean weight loss of approximately 19% for adults with overweight or obesity, according to a speaker.

Sleep-deprived postmenopausal women who catch up on their sleep over the weekend are less likely to have hyperuricemia than women who do not catch up on their sleep, according to findings published in Menopause.

Among patients with atrial fibrillation who chose to undergo catheter ablation, those who lost at least 3% of body weight before the procedure were more likely to be free from AF at 6 months, according to early results of the LEAF trial.

The U.S. Supreme Court unanimously ruled in favor of Regeneron and Sanofi that two of Amgen’s patents for PCSK9 inhibitor technology were invalid, allowing alirocumab to stay on the U.S. market.

Following a successful meeting in 2022, the Heart in Diabetes Conference is looking forward to hosting its seventh-annual meeting in Philadelphia in June.

Adults with type 2 diabetes who switched from liraglutide to semaglutide therapy had greater reductions in HbA1c and body weight at 26 weeks than those who switched to dulaglutide, according to study data from researchers in Japan.